Actualités Theratechnologies Inc - TH | Actions Toronto Stock Exchange

Theratechnologies Reports Financial Results for the Fourth Quarter and Full Year of Fiscal 2024

Achieved record positive Adjusted EBITDA* of $20 million for FY2024 (net loss of $8.3 million), exceeding...

Theratechnologies to Announce Fourth Quarter and Full Year 2024 Financial Results and Provide Business Update

MONTREAL, Feb. 14, 2025 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”...

Theratechnologies Resumes Distribution of EGRIFTA SV®

MONTREAL, Feb. 13, 2025 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”...

Theratechnologies Provides Update on EGRIFTA SV® Supply

MONTREAL, Jan. 09, 2025 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”...

Theratechnologies Announces Filing of FDA Prior Approval Supplement for EGRIFTA SV® Manufacturing Environment

MONTREAL, Dec. 18, 2024 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”...

Theratechnologies Receives March 2025 PDUFA Goal Date for Updated Tesamorelin F8 Formulation sBLA

MONTREAL, Dec. 10, 2024 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”...

Theratechnologies Announces Preliminary Tolerability and Efficacy Data from Phase 1b, Dose-Ranging Trial of Sudocetaxel Zendusortide in Patients with Advanced Ovarian Cancer

No dose-limiting toxicities reported in two different weekly doses in heavily pre-treated patients Preliminary...

Theratechnologies Announces Exclusive Licensing Agreement with Ionis to Commercialize Olezarsen and Donidalorsen in Canada

Addition of investigational RNA-targeted medicines build upon Theratechnologies’ foundational HIV portfolio...

Theratechnologies Announces Resumed Production of EGRIFTA SV®

MONTREAL, Dec. 03, 2024 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”...

Theratechnologies Secures up to $75 Million in New Credit Facilities with TD Bank and Investissement Québec

New financing replaces existing credit facility to optimize Company’s capital structureFavorable interest rates...

Theratechnologies Submits Updated Tesamorelin F8 Formulation sBLA for FDA Review

Resubmission addresses questions raised in January 2024 Complete Response Letter F8 formulation intended to...

Theratechnologies IDWeek Presentations Highlight the Impact of Excess Visceral Abdominal Fat (EVAF) on Cardiovascular Disease (CVD) Risk in People with HIV

MONTREAL, Oct. 17, 2024 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”...

Theratechnologies Unveils Study Design and Baseline Characteristics of PROMISE-US Trial of Ibalizumab in Heavily Treatment-Experienced People with HIV and Multidrug Resistance

MONTREAL, Oct. 17, 2024 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”...

Theratechnologies Reports Strong Financial Results and Announces Positive Net Income for Third Quarter 2024

Q3 revenue of $22.6 million represents +8% growth year-over-yearPositive net income of $3.1 million or 6 cents...

Theratechnologies to Present Data at IDWeek 2024 Highlighting Advances in Treatment and Management of Complications in People with HIV

MONTREAL, Oct. 09, 2024 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”...

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Theratechnologies Inc (TH)

Outils de qualité professionnelle, pour des investisseurs individuels.

TH Actualités

Theratechnologies Reports Financial Results for the Fourth Quarter and Full Year of Fiscal 2024

Theratechnologies to Announce Fourth Quarter and Full Year 2024 Financial Results and Provide Business Update

Theratechnologies Resumes Distribution of EGRIFTA SV®

Theratechnologies Provides Update on EGRIFTA SV® Supply

Theratechnologies Announces Filing of FDA Prior Approval Supplement for EGRIFTA SV® Manufacturing Environment

Theratechnologies Receives March 2025 PDUFA Goal Date for Updated Tesamorelin F8 Formulation sBLA

Theratechnologies Announces Preliminary Tolerability and Efficacy Data from Phase 1b, Dose-Ranging Trial of Sudocetaxel Zendusortide in Patients with Advanced Ovarian Cancer

Theratechnologies Announces Exclusive Licensing Agreement with Ionis to Commercialize Olezarsen and Donidalorsen in Canada

Theratechnologies Announces Resumed Production of EGRIFTA SV®

Theratechnologies Secures up to $75 Million in New Credit Facilities with TD Bank and Investissement Québec

Theratechnologies Submits Updated Tesamorelin F8 Formulation sBLA for FDA Review

Theratechnologies IDWeek Presentations Highlight the Impact of Excess Visceral Abdominal Fat (EVAF) on Cardiovascular Disease (CVD) Risk in People with HIV

Theratechnologies Unveils Study Design and Baseline Characteristics of PROMISE-US Trial of Ibalizumab in Heavily Treatment-Experienced People with HIV and Multidrug Resistance

Theratechnologies Reports Strong Financial Results and Announces Positive Net Income for Third Quarter 2024

Theratechnologies to Present Data at IDWeek 2024 Highlighting Advances in Treatment and Management of Complications in People with HIV

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Theratechnologies Inc (TH) Actualités

Theratechnologies Inc (TH)

Outils de qualité professionnelle, pour des investisseurs individuels.

TH Actualités

Theratechnologies Reports Financial Results for the Fourth Quarter and Full Year of Fiscal 2024

Theratechnologies to Announce Fourth Quarter and Full Year 2024 Financial Results and Provide Business Update

Theratechnologies Resumes Distribution of EGRIFTA SV®

Theratechnologies Provides Update on EGRIFTA SV® Supply

Theratechnologies Announces Filing of FDA Prior Approval Supplement for EGRIFTA SV® Manufacturing Environment

Theratechnologies Receives March 2025 PDUFA Goal Date for Updated Tesamorelin F8 Formulation sBLA

Theratechnologies Announces Preliminary Tolerability and Efficacy Data from Phase 1b, Dose-Ranging Trial of Sudocetaxel Zendusortide in Patients with Advanced Ovarian Cancer

Theratechnologies Announces Exclusive Licensing Agreement with Ionis to Commercialize Olezarsen and Donidalorsen in Canada

Theratechnologies Announces Resumed Production of EGRIFTA SV®

Theratechnologies Secures up to $75 Million in New Credit Facilities with TD Bank and Investissement Québec

Theratechnologies Submits Updated Tesamorelin F8 Formulation sBLA for FDA Review

Theratechnologies IDWeek Presentations Highlight the Impact of Excess Visceral Abdominal Fat (EVAF) on Cardiovascular Disease (CVD) Risk in People with HIV

Theratechnologies Unveils Study Design and Baseline Characteristics of PROMISE-US Trial of Ibalizumab in Heavily Treatment-Experienced People with HIV and Multidrug Resistance

Theratechnologies Reports Strong Financial Results and Announces Positive Net Income for Third Quarter 2024

Theratechnologies to Present Data at IDWeek 2024 Highlighting Advances in Treatment and Management of Complications in People with HIV

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Supprimer les publicités